Link Biologics
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Ophthalmology
Link Biologics is pioneering the development of protein biologics that harness the protective biology of tumour necrosis factor-stimulated gene-6 (TSG-6) and set new standards of care via multi-pathway modulation of inflammation, tissue protection and repair. With broad potential across inflammatory and degenerative conditions, the Company’s lead programmes focus on Dry Eye Disease (DED) and Wet Age-related Macular Degeneration (AMD); together these represent multi-billion-dollar global markets with significant unmet needs. Its lead asset, Link_TSG6, for the treatment of DED, is expected to reach the clinic in 2027 with a clear path to key, value-creating, milestones.
Led by a world-class team with decades of academic and commercial experience in TSG-6 biology and drug development, Link Biologics combines deep scientific and pharma leadership with a collaborative, outcome-driven culture, positioning the Company to deliver game-changing therapies.
Company HQ City:
London
Company HQ State:
London, United Kingdom
Company HQ Country:
United Kingdom
Year Founded:
2021
Lead Product in Development:
LB001 (Link_TSG6) for the treatment of Dry Eye Disease
CEO
Reuben Dawkins
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
1. May 2027
2. December 2028
What is your next catalyst (value inflection) update?
1. Entry into Phase 1/2 Clinical Trial
2. Clinical proof of concept (Phase 1/2 read out)
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}